{"url_path":"/sec/caba/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1759138/0001759138-26-000026-index.html","accession_number":"0001759138-26-000026","cik":"0001759138","ticker":"CABA","issuer_name":"Cabaletta Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1759138/0001759138-26-000026-index.html","primary_entity_key":"0001759138","primary_entity_name":"Cabaletta Bio, Inc."},"word_count":205,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nRule 10b5-1 Trading Plans\n\nDuring the fiscal quarter ended on March 31, 2026, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408(a) of Regulation S-K, except as described in the table below:\n\nName and Title\n\nAction\n\nAction Date\n\nDuration of Trading Arrangements(1)\n\nRule 10b5-1 Trading Arrangement?\n\n(Y/N)*\n\nAggregate Number of Securities Subject to Trading Arrangement\n\nSteven Nichtberger\n\nChief Executive Officer\n\nTerminate(2)\n\nJanuary 20, 2026\n\nFebruary 16, 2025 – August 28, 2026\n\nY\n\nUp to 350,000 shares to be sold\n\n* Denotes whether the trading plan is intended, when adopted, to satisfy the affirmative defense of Rule 10b5-1(c).\n\n(1) Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table.\n\n(2) Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written trading arrangement adopted on August 30, 2023 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.\n\n99"}